---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-037739"
form_type: "8-K"
ticker: "CODX"
cik: "0001692415"
company_name: "Co-Diagnostics, Inc."
filed_at: "2026-08-13T20:03:21+00:00"
generated_at: "2026-08-13T20:04:07.666475+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Co-Diagnostics Q2 net loss narrows to $6.3M; FDA 510(k) submitted for Flu/RSV test

## Summary
- Revenue $0.17M vs $0.16M YoY; net loss $6.3M ($1.46/share) vs $7.7M ($7.00) prior year.
- Operating loss $6.2M, improved from $8.1M; adjusted EBITDA loss $5.8M vs $7.2M; cash $3.6M.
- Submitted FDA 510(k) for Flu A/B & RSV test on PCR Pro; clinical study 1,400+ patients, 27 analytical studies, 10,000+ runs.
- Advanced Saudi manufacturing: industrial site approval and lease in Sudair Industrial City; distribution agreement in Mexico.
- Appointed Wes Lindsey, Ph.D. as Chief Scientific Officer; initiated TB studies in India via CoSara.

## SEC filing metadata
- accession: 0001493152-26-037739
- form_type: 8-K
- ticker: CODX
- cik: 0001692415
- company_name: Co-Diagnostics, Inc.
- filed_at: 2026-08-13T20:03:21+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1692415/000149315226037739/0001493152-26-037739-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1692415/000149315226037739/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-037739
- JSON: https://secwatch.observer/filing/0001493152-26-037739.json
- Plain text: https://secwatch.observer/filing/0001493152-26-037739.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.